Matches in SemOpenAlex for { <https://semopenalex.org/work/W2343159740> ?p ?o ?g. }
- W2343159740 endingPage "304" @default.
- W2343159740 startingPage "296" @default.
- W2343159740 abstract "Background & Aims The purpose of this study was to determine whether biomarkers from baseline plasma and archival tissue specimens collected from patients enrolled in the EVOLVE-1 trial – a randomized phase 3 study of everolimus in hepatocellular carcinoma (HCC) – were associated with prognosis, etiology or ethnicity. Methods Circulating plasma levels of bFGF, PLGF, VEGF, VEGF-D, c-Kit, collagen IV, sVEGFR1 and VEGFR2 were measured by ELISA (N = 503). Protein levels of IGF-1R, c-Met, mTOR, Tsc2 were assayed by immunohistochemistry (N = 125). Genomic DNA sequencing was conducted on a panel of 287 cancer-related genes (N = 69). Results Patients with baseline plasma concentrations of VEGF or sVEGFR1 above the cohort median had significantly shorter overall survival. These plasma biomarkers retained prognostic significance in a multivariate Cox regression model with geographic region, macroscopic vascular invasion and alpha fetoprotein AFP levels. Membranous c-Met protein levels were significantly lower for Asian patients, as well as for hepatitis B viral etiology. The prevalence of genetic changes were similar to previous reports, along with a trend towards higher PTEN and TSC2 mutations among Asians. Conclusions The angiogenesis biomarkers VEGF and sVEGFR1 were independent prognostic predictors of survival in patients with advanced HCC. Potential differences in c-Met and mTOR pathway activation between Asian and non-Asian patients should be considered in future clinical trials. Lay summary Our study demonstrates that circulating angiogenesis biomarkers can predict the survival outcome in patients with advanced hepatocellular carcinoma independent of the clinical variables. There is etiology and ethnicity variation in molecular pathway activation in hepatocellular carcinoma, which should be considered for future clinical trial design of targeted therapy. Clinical trial registration number: NCT01035229. The purpose of this study was to determine whether biomarkers from baseline plasma and archival tissue specimens collected from patients enrolled in the EVOLVE-1 trial – a randomized phase 3 study of everolimus in hepatocellular carcinoma (HCC) – were associated with prognosis, etiology or ethnicity. Circulating plasma levels of bFGF, PLGF, VEGF, VEGF-D, c-Kit, collagen IV, sVEGFR1 and VEGFR2 were measured by ELISA (N = 503). Protein levels of IGF-1R, c-Met, mTOR, Tsc2 were assayed by immunohistochemistry (N = 125). Genomic DNA sequencing was conducted on a panel of 287 cancer-related genes (N = 69). Patients with baseline plasma concentrations of VEGF or sVEGFR1 above the cohort median had significantly shorter overall survival. These plasma biomarkers retained prognostic significance in a multivariate Cox regression model with geographic region, macroscopic vascular invasion and alpha fetoprotein AFP levels. Membranous c-Met protein levels were significantly lower for Asian patients, as well as for hepatitis B viral etiology. The prevalence of genetic changes were similar to previous reports, along with a trend towards higher PTEN and TSC2 mutations among Asians. The angiogenesis biomarkers VEGF and sVEGFR1 were independent prognostic predictors of survival in patients with advanced HCC. Potential differences in c-Met and mTOR pathway activation between Asian and non-Asian patients should be considered in future clinical trials." @default.
- W2343159740 created "2016-06-24" @default.
- W2343159740 creator A5005925636 @default.
- W2343159740 creator A5015257936 @default.
- W2343159740 creator A5018333718 @default.
- W2343159740 creator A5037162298 @default.
- W2343159740 creator A5056197140 @default.
- W2343159740 creator A5061222063 @default.
- W2343159740 creator A5063447892 @default.
- W2343159740 creator A5078521606 @default.
- W2343159740 creator A5079238859 @default.
- W2343159740 creator A5079645039 @default.
- W2343159740 creator A5086015556 @default.
- W2343159740 creator A5088566246 @default.
- W2343159740 date "2016-08-01" @default.
- W2343159740 modified "2023-10-16" @default.
- W2343159740 title "Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma" @default.
- W2343159740 cites W1522860394 @default.
- W2343159740 cites W1863396492 @default.
- W2343159740 cites W1971837077 @default.
- W2343159740 cites W1988303870 @default.
- W2343159740 cites W2001406613 @default.
- W2343159740 cites W2010129267 @default.
- W2343159740 cites W2012346684 @default.
- W2343159740 cites W2018080595 @default.
- W2343159740 cites W2018851752 @default.
- W2343159740 cites W2019832083 @default.
- W2343159740 cites W2021080283 @default.
- W2343159740 cites W2023250239 @default.
- W2343159740 cites W2023815439 @default.
- W2343159740 cites W2025344915 @default.
- W2343159740 cites W2036922484 @default.
- W2343159740 cites W2042571415 @default.
- W2343159740 cites W2048177238 @default.
- W2343159740 cites W2060043441 @default.
- W2343159740 cites W2064024065 @default.
- W2343159740 cites W2068127752 @default.
- W2343159740 cites W2070489177 @default.
- W2343159740 cites W2073618702 @default.
- W2343159740 cites W2101650407 @default.
- W2343159740 cites W2102942095 @default.
- W2343159740 cites W2105327344 @default.
- W2343159740 cites W2111070218 @default.
- W2343159740 cites W2111945133 @default.
- W2343159740 cites W2112489161 @default.
- W2343159740 cites W2113686775 @default.
- W2343159740 cites W2118151336 @default.
- W2343159740 cites W2118231569 @default.
- W2343159740 cites W2123546830 @default.
- W2343159740 cites W2127949876 @default.
- W2343159740 cites W2128965737 @default.
- W2343159740 cites W2132711541 @default.
- W2343159740 cites W2136415416 @default.
- W2343159740 cites W2139504369 @default.
- W2343159740 cites W2140587309 @default.
- W2343159740 cites W2146781227 @default.
- W2343159740 cites W2148424438 @default.
- W2343159740 cites W2155514044 @default.
- W2343159740 cites W2158378236 @default.
- W2343159740 cites W2160981405 @default.
- W2343159740 cites W2162242700 @default.
- W2343159740 cites W2164241627 @default.
- W2343159740 cites W2171402611 @default.
- W2343159740 cites W2172031801 @default.
- W2343159740 cites W2187235615 @default.
- W2343159740 cites W2289555820 @default.
- W2343159740 cites W2312282875 @default.
- W2343159740 cites W4245403358 @default.
- W2343159740 doi "https://doi.org/10.1016/j.jhep.2016.04.015" @default.
- W2343159740 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27130844" @default.
- W2343159740 hasPublicationYear "2016" @default.
- W2343159740 type Work @default.
- W2343159740 sameAs 2343159740 @default.
- W2343159740 citedByCount "24" @default.
- W2343159740 countsByYear W23431597402016 @default.
- W2343159740 countsByYear W23431597402017 @default.
- W2343159740 countsByYear W23431597402018 @default.
- W2343159740 countsByYear W23431597402019 @default.
- W2343159740 countsByYear W23431597402020 @default.
- W2343159740 countsByYear W23431597402021 @default.
- W2343159740 countsByYear W23431597402022 @default.
- W2343159740 countsByYear W23431597402023 @default.
- W2343159740 crossrefType "journal-article" @default.
- W2343159740 hasAuthorship W2343159740A5005925636 @default.
- W2343159740 hasAuthorship W2343159740A5015257936 @default.
- W2343159740 hasAuthorship W2343159740A5018333718 @default.
- W2343159740 hasAuthorship W2343159740A5037162298 @default.
- W2343159740 hasAuthorship W2343159740A5056197140 @default.
- W2343159740 hasAuthorship W2343159740A5061222063 @default.
- W2343159740 hasAuthorship W2343159740A5063447892 @default.
- W2343159740 hasAuthorship W2343159740A5078521606 @default.
- W2343159740 hasAuthorship W2343159740A5079238859 @default.
- W2343159740 hasAuthorship W2343159740A5079645039 @default.
- W2343159740 hasAuthorship W2343159740A5086015556 @default.
- W2343159740 hasAuthorship W2343159740A5088566246 @default.
- W2343159740 hasConcept C121608353 @default.
- W2343159740 hasConcept C126322002 @default.
- W2343159740 hasConcept C137627325 @default.